2020
Who is at risk of 13-valent conjugated pneumococcal vaccine failure?
Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I. Who is at risk of 13-valent conjugated pneumococcal vaccine failure? Vaccine 2020, 38: 1671-1677. PMID: 31974018, DOI: 10.1016/j.vaccine.2019.12.060.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine failureIPD casesVaccine serotypesDiagnosis of IPDHigh vaccine coverage ratesPneumococcal conjugate vaccineVaccine coverage ratesUnderlying risk factorsYears of ageMonths of agePneumococcal pneumoniaImmunization PracticesVaccine scheduleConjugate vaccinePneumococcal diseasePrimary dosesClinical presentationImmunization scheduleSerotype 19ACourse of immunisationRisk factorsComorbiditiesStudy periodPassive surveillance
2017
Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness
Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, Pelton SI, T, Health H. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine 2017, 35: 4002-4009. PMID: 28645717, DOI: 10.1016/j.vaccine.2017.05.077.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineInvasive disease potentialPneumococcal diseaseLow invasive capacityInvasive capacityPCV13 eraCommon serotypesIncidence of IPDNasopharyngeal colonization ratePost-vaccine eraDisease potentialCarriage serotypesPCV eraConjugate vaccineNasopharyngeal carriageCarriage prevalencePneumococcal colonizationEnhanced surveillanceDynamic epidemiologyAge groupsSerotype 3Serotype XOlder childrenLow invasiveness
2015
Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease
Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease. Pediatrics 2015, 135: 495-503. PMID: 25647674, DOI: 10.1542/peds.2014-2426.Peer-Reviewed Original ResearchMeSH KeywordsBacterial CapsulesChildChild, PreschoolComorbidityFemaleFollow-Up StudiesHumansIncidenceInfantMaleMassachusettsPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillancePrognosisRetrospective StudiesRisk AssessmentRisk FactorsStreptococcus pneumoniaeVaccinationVaccines, ConjugateConceptsInvasive pneumococcal diseasePneumococcal diseaseUnderlying conditionOutcomes of IPDPrevention of IPDChildhood invasive pneumococcal diseasePneumococcal vaccination statusPolysaccharide pneumococcal vaccineYear of diagnosisPrimary care providersCase fatality rateChronic respiratory diseasesImmunocompromising conditionsIPD diagnosisUnderlying comorbiditiesImmunization PracticesIPD casesPneumococcal vaccineVaccination statusConjugate vaccineMassachusetts childrenClinical presentationSerotype distributionHigher hospitalizationClinical data
2012
Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children
Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children. The Pediatric Infectious Disease Journal 2012, 31: 1016-1021. PMID: 22673142, DOI: 10.1097/inf.0b013e3182615615.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Bacterial AgentsChildChild, PreschoolCluster AnalysisFemaleHeptavalent Pneumococcal Conjugate VaccineHumansIncidenceInfantMaleMassachusettsMeningitis, PneumococcalMicrobial Sensitivity TestsMultilocus Sequence TypingPneumococcal VaccinesProspective StudiesSepsisSerotypingStreptococcus pneumoniaeConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccine serotypesPneumococcal conjugate vaccineIPD incidence ratesMassachusetts childrenPCV7 eraIPD casesPneumococcal diseaseConjugate vaccineVaccine serotypesSerotype 19AIncidence rateCases of IPDChildhood invasive pneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePopulation-based surveillanceOverall IPD incidence ratesCeftriaxone-resistant isolatesYears of ageAntimicrobial susceptibility testingBacteremic pneumoniaPCV7 serotypesMultilocus sequence typingNonvaccine serotypesClinical presentation
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X